Pro-angiogenic effect of RANTES-loaded polysaccharide-based microparticles for a mouse ischemia therapy

[1]  Ça Ira , 2019, The Totality for Kids.

[2]  T. Lüscher.  An update on heart failure: from experimental findings to clinical trials. , 2017, European heart journal.

[3]  J. Y. Lee,et al.  Chemokine Ligand 5 (CCL5) Derived from Endothelial Colony-Forming Cells (ECFCs) Mediates Recruitment of Smooth Muscle Progenitor Cells (SPCs) toward Critical Vascular Locations in Moyamoya Disease , 2017, PloS one.

[4]  A. Dinner,et al.  Structural basis for oligomerization and glycosaminoglycan binding of CCL5 and CCL3 , 2016, Proceedings of the National Academy of Sciences.

[5]  Federico Ambrogi,et al.  Magnetic Resonance Imaging Allows the Evaluation of Tissue Damage and Regeneration in a Mouse Model of Critical Limb Ischemia , 2015, PloS one.

[6]  P. Albanese,et al.  A fine structural modification of glycosaminoglycans is correlated with the progression of muscle regeneration after ischaemia: towards a matrix-based therapy? , 2015, European cells & materials.

[7]  C. Lobe,et al.  CCR5 facilitates endothelial progenitor cell recruitment and promotes the stabilization of atherosclerotic plaques in ApoE−/− mice , 2015, Stem Cell Research & Therapy.

[8]  Chun-Hao Tsai,et al.  CCL5 promotes vascular endothelial growth factor expression and induces angiogenesis by down-regulating miR-199a in human chondrosarcoma cells. , 2015, Cancer letters.

[9]  E. K. Yim,et al.  Composite Scaffold of Poly(Vinyl Alcohol) and Interfacial Polyelectrolyte Complexation Fibers for Controlled Biomolecule Delivery , 2015, Front. Bioeng. Biotechnol..

[10]  D. Mooney,et al.  Local delivery of VEGF and SDF enhances endothelial progenitor cell recruitment and resultant recovery from ischemia. , 2015, Tissue engineering. Part A.

[11]  Hui-Lung Sun,et al.  CCL5/CCR5 axis induces vascular endothelial growth factor-mediated tumor angiogenesis in human osteosarcoma microenvironment. , 2015, Carcinogenesis.

[12]  T. Tan,et al.  CCL5 promotes VEGF-dependent angiogenesis by down-regulating miR-200b through PI3K/Akt signaling pathway in human chondrosarcoma cells , 2014, Oncotarget.

[13]  Nathaniel S. Hwang,et al.  Injectable multifunctional microgel encapsulating outgrowth endothelial cells and growth factors for enhanced neovascularization. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[14]  Andrew Hopkinson,et al.  Concise Review: Evidence for CD34 as a Common Marker for Diverse Progenitors , 2014, Stem cells.

[15]  S. Y. Chew,et al.  Polysaccharide electrospun fibers with sulfated poly(fucose) promote endothelial cell migration and VEGF-mediated angiogenesis. , 2014, Biomaterials science.

[16]  J. Temenoff,et al.  Molecular engineering of glycosaminoglycan chemistry for biomolecule delivery. , 2014, Acta biomaterialia.

[17]  D. Letourneur,et al.  Abdominal Aortic Aneurysms Targeted by Functionalized Polysaccharide Microparticles: a new Tool for SPECT Imaging , 2014, Theranostics.

[18]  D. Mantovani,et al.  Fucoidan in a 3D scaffold interacts with vascular endothelial growth factor and promotes neovascularization in mice , 2015, Drug Delivery and Translational Research.

[19]  A. Józkowicz,et al.  Therapeutic angiogenesis for revascularization in peripheral artery disease. , 2013, Gene.

[20]  R. Stilhano,et al.  Comparison of treatments of peripheral arterial disease with mesenchymal stromal cells and mesenchymal stromal cells modified with granulocyte and macrophage colony-stimulating factor. , 2013, Cytotherapy.

[21]  Zhi-Sheng Jiang,et al.  Apolipoprotein (a) impairs endothelial progenitor cell-mediated angiogenesis. , 2013, DNA and cell biology.

[22]  Douglas Losordo,et al.  Cell therapy of peripheral arterial disease: from experimental findings to clinical trials. , 2013, Circulation research.

[23]  Baohui Xu,et al.  Peptide Inhibitor of CXCL4–CCL5 Heterodimer Formation, MKEY, Inhibits Experimental Aortic Aneurysm Initiation and Progression , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[24]  Hsin-Chieh Yeh,et al.  Effect of the 2011 vs 2003 duty hour regulation-compliant models on sleep duration, trainee education, and continuity of patient care among internal medicine house staff: a randomized trial. , 2013, JAMA internal medicine.

[25]  Shingo Nakamura,et al.  Attenuation of limb loss in an experimentally induced hindlimb ischemic model by fibroblast growth factor-2/fragmin/protamine microparticles as a delivery system. , 2012, Tissue engineering. Part A.

[26]  D. Letourneur,et al.  Porous polysaccharide-based scaffolds for human endothelial progenitor cells. , 2012, Macromolecular bioscience.

[27]  A. Sutton,et al.  RANTES/CCL5-induced pro-angiogenic effects depend on CCR1, CCR5 and glycosaminoglycans , 2012, Angiogenesis.

[28]  E. Chavakis,et al.  Sustained delivery of SDF-1α from heparin-based hydrogels to attract circulating pro-angiogenic cells. , 2012, Biomaterials.

[29]  K. Matsushima,et al.  Pivotal role of the CCL5/CCR5 interaction for recruitment of endothelial progenitor cells in mouse wound healing. , 2012, The Journal of clinical investigation.

[30]  P. Bruneval,et al.  Therapeutic effect of fucoidan‐stimulated endothelial colony‐forming cells in peripheral ischemia , 2012, Journal of thrombosis and haemostasis : JTH.

[31]  Jean-Baptiste Michel,et al.  Mesenchymal stem cell delivery into rat infarcted myocardium using a porous polysaccharide-based scaffold: a quantitative comparison with endocardial injection. , 2012, Tissue engineering. Part A.

[32]  A. Sutton,et al.  Angiogenic properties of the chemokine RANTES/CCL5. , 2011, Biochemical Society transactions.

[33]  V. Vanneaux,et al.  Cord blood‐circulating endothelial progenitors for treatment of vascular diseases , 2011, Cell proliferation.

[34]  Carlos Ortiz-de-Solorzano,et al.  Sustained release of VEGF through PLGA microparticles improves vasculogenesis and tissue remodeling in an acute myocardial ischemia-reperfusion model. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[35]  B. Lévy,et al.  Regulation of monocyte subset systemic levels by distinct chemokine receptors controls post-ischaemic neovascularization. , 2010, Cardiovascular research.

[36]  D. Letourneur,et al.  Films of dextran-graft-polybutylmethacrylate to enhance endothelialization of materials. , 2010, Acta biomaterialia.

[37]  F. Chaubet,et al.  Fabrication of porous polysaccharide-based scaffolds using a combined freeze-drying/cross-linking process. , 2010, Acta biomaterialia.

[38]  A. Bikfalvi,et al.  Interaction of PF4 (CXCL4) with the vasculature: A role in atherosclerosis and angiogenesis , 2010, Thrombosis and Haemostasis.

[39]  B. Gafsou,et al.  &agr;6-Integrin Subunit Plays a Major Role in the Proangiogenic Properties of Endothelial Progenitor Cells , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[40]  C. Weber,et al.  Chemokine CCL5/RANTES inhibition reduces myocardial reperfusion injury in atherosclerotic mice. , 2010, Journal of molecular and cellular cardiology.

[41]  Masafumi Takahashi.  Role of the SDF-1/CXCR4 system in myocardial infarction. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[42]  Loïc Martin,et al.  Syndecan-1 and syndecan-4 are involved in RANTES/CCL5-induced migration and invasion of human hepatoma cells. , 2009, Biochimica et biophysica acta.

[43]  M. Teixeira,et al.  Role of the chemokines CCL3/MIP-1 alpha and CCL5/RANTES in sponge-induced inflammatory angiogenesis in mice. , 2009, Microvascular research.

[44]  C. Weber,et al.  The basic residue cluster (55)KKWVR(59) in CCL5 is required for in vivo biologic function. , 2009, Molecular immunology.

[45]  M. Simons,et al.  The Antiangiogenic Activity of rPAI-123 Inhibits Vasa Vasorum and Growth of Atherosclerotic Plaque , 2009, Circulation research.

[46]  T. Nishibe,et al.  Limb ischemia after iliac ligation in aged mice stimulates angiogenesis without arteriogenesis. , 2009, Journal of vascular surgery.

[47]  G. Moneta.  Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia , 2009 .

[48]  H. Matsubara,et al.  Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia. , 2008, American heart journal.

[49]  M. Mack,et al.  CC family chemokines directly regulate myoblast responses to skeletal muscle injury , 2008, The Journal of physiology.

[50]  M. Grounds,et al.  Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy , 2008, Neurobiology of Disease.

[51]  T. Rabelink,et al.  RANTES is required for ischaemia-induced angiogenesis, which may hamper RANTES-targeted anti-atherosclerotic therapy , 2008, Thrombosis and Haemostasis.

[52]  Loïc Martin,et al.  Glycosaminoglycans and their synthetic mimetics inhibit RANTES-induced migration and invasion of human hepatoma cells , 2007, Molecular Cancer Therapeutics.

[53]  T. Rabelink,et al.  Met-RANTES reduces endothelial progenitor cell homing to activated (glomerular) endothelium in vitro and in vivo. , 2007, American journal of physiology. Renal physiology.

[54]  Paula K Shireman,et al.  The chemokine system in arteriogenesis and hind limb ischemia. , 2007, Journal of vascular surgery.

[55]  F. Petersen,et al.  Platelet-derived chemokines in vascular biology , 2007, Thrombosis and Haemostasis.

[56]  J. Tidball,et al.  Macrophages promote muscle membrane repair and muscle fibre growth and regeneration during modified muscle loading in mice in vivo , 2007, The Journal of physiology.

[57]  L. McManus,et al.  MCP-1 parallels inflammatory and regenerative responses in ischemic muscle. , 2006, The Journal of surgical research.

[58]  M. Goligorsky,et al.  Therapeutic use of stem and endothelial progenitor cells in acute renal injury: ça ira. , 2006, Current opinion in pharmacology.

[59]  D. Benisvy,et al.  Low-molecular-weight fucoidan enhances the proangiogenic phenotype of endothelial progenitor cells. , 2005, Biochemical pharmacology.

[60]  Sunjoo Jeong,et al.  Inhibition of the angiogenesis by the MCP‐1 (monocyte chemoattractant protein‐1) binding peptide , 2005, FEBS letters.

[61]  M. Pesce,et al.  SDF-1 involvement in endothelial phenotype and ischemia-induced recruitment of bone marrow progenitor cells. , 2004, Blood.

[62]  F. Mach,et al.  Antagonism of RANTES Receptors Reduces Atherosclerotic Plaque Formation in Mice , 2004, Circulation research.

[63]  D. Scholz,et al.  Angiogenesis and myogenesis as two facets of inflammatory post-ischemic tissue regeneration , 2002, Molecular and Cellular Biochemistry.

[64]  C. Vita,et al.  Interaction of RANTES with syndecan-1 and syndecan-4 expressed by human primary macrophages. , 2003, Biochimica et biophysica acta.

[65]  C. Vita,et al.  Binding of the CC-chemokine RANTES to syndecan-1 and syndecan-4 expressed on HeLa cells. , 2003, Glycobiology.

[66]  Owen D Williamson,et al.  Determining the sample size in a clinical trial , 2003, The Medical journal of Australia.

[67]  J. Isner,et al.  Stromal Cell–Derived Factor-1 Effects on Ex Vivo Expanded Endothelial Progenitor Cell Recruitment for Ischemic Neovascularization , 2003, Circulation.

[68]  J. Ambati,et al.  Sustained inhibition of corneal neovascularization by genetic ablation of CCR5. , 2003, Investigative ophthalmology & visual science.

[69]  D. Ribatti,et al.  Analysis of the role of chemokines in angiogenesis. , 2003, Journal of immunological methods.

[70]  R. Lederman,et al.  Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomized trial☆ , 2002 .

[71]  R. Lederman,et al.  Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial , 2002, The Lancet.

[72]  S. Adamopoulos,et al.  Serum profiles of C-C chemokines in acute myocardial infarction: possible implication in postinfarction left ventricular remodeling. , 2002, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[73]  R.,et al.  Rapid Mobilization of Hematopoietic Progenitor Cells in Rhesus Monkeys by a Single Intravenous Injection of Interleukin-8 , 2002 .

[74]  L. Cooper,et al.  Proteinuria in a placebo-controlled study of basic fibroblast growth factor for intermittent claudication , 2001, Vascular medicine.

[75]  S. Salani,et al.  Chemotactic factors enhance myogenic cell migration across an endothelial monolayer. , 2001, Experimental cell research.

[76]  J. Ward,et al.  Eotaxin (CCL11) Induces In Vivo Angiogenic Responses by Human CCR3+ Endothelial Cells1 , 2001, The Journal of Immunology.

[77]  A. Trkola,et al.  The BBXB Motif of RANTES Is the Principal Site for Heparin Binding and Controls Receptor Selectivity* , 2001, The Journal of Biological Chemistry.

[78]  A. Quyyumi,et al.  Basic fibroblast growth factor in patients with intermittent claudication: results of a phase I trial. , 2000, Journal of the American College of Cardiology.

[79]  E. Whitehorn,et al.  Receptor-mediated Endocytosis of CC-chemokines* , 1997, The Journal of Biological Chemistry.

[80]  I M TARLOV,et al.  Spinal cord compression studies. II. Time limits for recovery after acute compression in dogs. , 1954, A.M.A. archives of neurology and psychiatry.

[81]  I. Tarlov.  Spinal cord compression studies. III. Time limits for recovery after gradual compression in dogs. , 1954, A.M.A. archives of neurology and psychiatry.

[82]  A. Cant.  Therapeutic , 1867, The Dental register.